Enbrel costs around $8,150 per month without insurance, making it one of the most expensive medications on the market. A single 50-milligram syringe carries a list price of $2,039.40. The reasons behind that price involve patent strategy, a rebate system that rewards high prices, decades of unchecked price increases, and the absence of any competing alternatives in the U.S.
How Enbrel’s Price Has Grown Over Time
When Enbrel launched in November 1998, it was already an expensive specialty drug. But the price today bears almost no resemblance to where it started. According to a 2023 affordability review by the Colorado Department of Insurance, Enbrel’s wholesale cost has increased 1,582% from its launch through January 2024. That’s not a typo. The drug’s price has grown roughly sixteen times over, far outpacing general inflation during the same period.
The increases haven’t slowed down either. In the past five years alone, the price rose about 40%. The most recent bump, a 5% increase from 2023 to 2024, came on top of a price that was already among the highest for any biologic drug. Amgen, Enbrel’s manufacturer, generated $3.3 billion in revenue from the drug in 2024, with $3.29 billion of that coming from U.S. sales alone. The American market is where the pricing power lives.
Patents That Block All Competition
The biggest structural reason Enbrel remains so expensive is that no competing version can legally be sold in the United States. Two biosimilars (essentially generic versions of biologic drugs) have been approved by the FDA: Erelzi in 2016 and Eticovo in 2019. Both cleared the same safety and efficacy standards. Neither has reached U.S. pharmacies.
That’s because Amgen holds multiple patents on Enbrel that extend well beyond the drug’s original exclusivity period. Two key patents, one covering the drug itself and another covering how it’s manufactured, block biosimilar competitors from entering the market until 2029 at the earliest. This kind of layered patent protection, sometimes called a “patent thicket,” is a common strategy among biologic drugmakers. By obtaining additional patents on manufacturing methods, formulations, or delivery devices over time, a company can extend its monopoly years beyond what the original patent allowed.
In most other developed countries, biosimilar competition has already driven prices for comparable drugs significantly lower. In the U.S., the patent wall around Enbrel has kept that from happening.
The Rebate System That Rewards High Prices
Even if you accept that making a complex biologic drug is expensive, Enbrel’s list price doesn’t reflect only manufacturing and research costs. It also reflects a pricing dynamic created by pharmacy benefit managers, the middlemen who negotiate drug prices on behalf of insurance plans.
Here’s how it works: PBMs negotiate rebates from drugmakers in exchange for placing their products on insurance formularies (the lists of covered drugs). The higher the list price, the larger the rebate a manufacturer can offer. A larger rebate makes a PBM more likely to give that drug preferred placement. This creates a perverse incentive where raising the list price actually improves a drug’s competitive position with insurers.
Colorado’s affordability review data illustrates the gap this creates. The average amount health plans actually paid per patient per year for Enbrel was about $53,000, while the maximum fair price calculated by Medicare was roughly $30,400. That’s a meaningful spread, and neither figure matches the sticker price a patient without insurance would face. The rebate dollars flow between the manufacturer and the PBM, but they don’t necessarily translate into lower costs for the person at the pharmacy counter.
This system has been tested in real-world conditions. When biosimilar competitors to another major biologic (adalimumab, sold as Humira) entered the market, some manufacturers tried offering low-list-price versions while others offered high-list-price versions with large rebates attached. Health plans overwhelmingly chose the high-price, high-rebate option. The Federal Trade Commission has since sued the three dominant PBMs, alleging they deliberately excluded lower-priced drugs in favor of higher-priced alternatives that generated bigger rebates. The same dynamics apply to Enbrel’s pricing.
No Generic Alternative Exists for Biologics
Enbrel is a biologic drug, meaning it’s produced using living cells rather than chemical synthesis. This matters for pricing because biologics can’t be copied the way a traditional pill can. A generic version of ibuprofen is chemically identical to the brand name. A biosimilar to Enbrel is highly similar but not an exact replica, because the manufacturing process with living organisms introduces inherent variability.
That complexity makes biosimilars far more expensive to develop than traditional generics. Companies spend hundreds of millions of dollars on clinical trials to prove their biosimilar works as well as the original. This higher barrier to entry means fewer competitors attempt it, and those that do still need to price their product high enough to recoup development costs. Even when biosimilars do reach the market for other drugs, they typically offer discounts of 15% to 40% rather than the 80% to 90% drops seen with traditional generics.
What Could Bring the Price Down
Two forces are converging that could change Enbrel’s pricing in the next few years. The first is the expiration of Amgen’s key patents in 2029, which would finally open the door for biosimilar competitors to enter the U.S. market. If even one or two biosimilars launch, historical precedent with other biologics suggests prices would drop meaningfully, though not as dramatically as with traditional generic drugs.
The second is Medicare price negotiation under the Inflation Reduction Act. Enbrel was among the first ten drugs selected for price negotiation, with a negotiated price set to take effect in 2026. While the exact negotiated figure hasn’t been widely published yet, the program’s structure requires the final price to reflect a significant discount from the current list price. This would directly affect what Medicare pays, though the impact on commercial insurance prices is less certain.
For patients paying out of pocket right now, Amgen offers a copay assistance card that can reduce costs for those with commercial insurance. Patients without insurance or on government plans have fewer options, though Amgen does run a separate patient assistance program for eligible individuals. The gap between a roughly $98,000 annual list price and what any individual can reasonably afford remains one of the starkest examples of how biologic drug pricing works in the U.S.